CN1152857C - 用作多巴胺受体的苯磺酰胺-苯乙胺 - Google Patents

用作多巴胺受体的苯磺酰胺-苯乙胺 Download PDF

Info

Publication number
CN1152857C
CN1152857C CNB998052175A CN99805217A CN1152857C CN 1152857 C CN1152857 C CN 1152857C CN B998052175 A CNB998052175 A CN B998052175A CN 99805217 A CN99805217 A CN 99805217A CN 1152857 C CN1152857 C CN 1152857C
Authority
CN
China
Prior art keywords
ethyl
phenyl
compound
propylamine
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998052175A
Other languages
English (en)
Chinese (zh)
Other versions
CN1297431A (zh
Inventor
A��G����÷��
A·G·罗梅罗
J·A·利比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of CN1297431A publication Critical patent/CN1297431A/zh
Application granted granted Critical
Publication of CN1152857C publication Critical patent/CN1152857C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB998052175A 1998-05-14 1999-05-07 用作多巴胺受体的苯磺酰胺-苯乙胺 Expired - Fee Related CN1152857C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8549398P 1998-05-14 1998-05-14
US60/085,493 1998-05-14

Publications (2)

Publication Number Publication Date
CN1297431A CN1297431A (zh) 2001-05-30
CN1152857C true CN1152857C (zh) 2004-06-09

Family

ID=22191975

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998052175A Expired - Fee Related CN1152857C (zh) 1998-05-14 1999-05-07 用作多巴胺受体的苯磺酰胺-苯乙胺

Country Status (24)

Country Link
US (1) US6103766A (https=)
EP (1) EP1077935B1 (https=)
JP (1) JP2002514623A (https=)
KR (1) KR20010043546A (https=)
CN (1) CN1152857C (https=)
AT (1) ATE253045T1 (https=)
AU (1) AU752543B2 (https=)
BR (1) BR9910405A (https=)
CA (1) CA2327345A1 (https=)
DE (1) DE69912419T2 (https=)
DK (1) DK1077935T3 (https=)
EA (1) EA002918B1 (https=)
ES (1) ES2211078T3 (https=)
HU (1) HUP0101746A3 (https=)
IL (1) IL139263A0 (https=)
NO (1) NO20005732D0 (https=)
NZ (1) NZ508152A (https=)
PL (1) PL343891A1 (https=)
PT (1) PT1077935E (https=)
SK (1) SK16242000A3 (https=)
TR (1) TR200003325T2 (https=)
TW (1) TW450954B (https=)
WO (1) WO1999058499A1 (https=)
ZA (1) ZA200005921B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225960B1 (en) * 1997-02-27 2008-01-28 Takeda Pharmaceutical Amine compounds, their production and use
EP1385495A4 (en) * 2001-05-07 2005-12-21 Smithkline Beecham Corp SULPHONAMIDES
JP2004535390A (ja) * 2001-05-07 2004-11-25 スミスクライン・ビーチャム・コーポレイション スルホンアミド
ATE520659T1 (de) 2004-10-14 2011-09-15 Abbott Gmbh & Co Kg Zur behandlung von auf die modulation des dopamin-d3-rezeptors ansprechenden erkrankungen geeignete azabicycloheptylverbindungen
ES2364488T3 (es) 2004-10-14 2011-09-05 ABBOTT GMBH & CO. KG Compuestos heterocíclicos adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina.
ES2380565T3 (es) * 2004-10-14 2012-05-16 Abbott Gmbh & Co. Kg Compuestos aminoetilaromáticos adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3
JP5232987B2 (ja) * 2006-04-14 2013-07-10 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアリールオキシエチルアミン化合物
PE20080057A1 (es) * 2006-04-14 2008-03-10 Abbott Gmbh & Co Kg Compuestos de ariloxietilamina como agentes moduladores del receptor de dopamina d3
TW200808762A (en) 2006-04-19 2008-02-16 Abbott Gmbh & Co Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
CA2648891A1 (en) 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
WO2008026046A1 (en) * 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3574741A (en) * 1969-04-14 1971-04-13 Mead Johnson & Co Sulfonamidophenalkylamines
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
GB9402197D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Compounds
AU4368996A (en) * 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
TR199802284T2 (xx) * 1996-05-11 2000-05-22 Smithkline Beecham P.L.C. Dopamin D3 resept�rlerinin mod�lat�rleri olarak tetrahidroizokuinolin t�revleri.
WO1998003473A1 (en) * 1996-07-22 1998-01-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
JPH1180156A (ja) * 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体

Also Published As

Publication number Publication date
AU752543B2 (en) 2002-09-19
NO20005732L (no) 2000-11-13
PT1077935E (pt) 2004-03-31
NZ508152A (en) 2003-03-28
BR9910405A (pt) 2001-01-09
CN1297431A (zh) 2001-05-30
DE69912419T2 (de) 2004-07-22
AU3741899A (en) 1999-11-29
PL343891A1 (en) 2001-09-10
DE69912419D1 (de) 2003-12-04
HK1036049A1 (en) 2001-12-21
EP1077935B1 (en) 2003-10-29
ZA200005921B (en) 2001-11-14
KR20010043546A (ko) 2001-05-25
ES2211078T3 (es) 2004-07-01
WO1999058499A1 (en) 1999-11-18
JP2002514623A (ja) 2002-05-21
TR200003325T2 (tr) 2001-04-20
DK1077935T3 (da) 2004-02-16
US6103766A (en) 2000-08-15
NO20005732D0 (no) 2000-11-13
EA200001184A1 (ru) 2001-04-23
TW450954B (en) 2001-08-21
EP1077935A1 (en) 2001-02-28
CA2327345A1 (en) 1999-11-18
IL139263A0 (en) 2001-11-25
EA002918B1 (ru) 2002-10-31
HUP0101746A2 (hu) 2002-03-28
HUP0101746A3 (en) 2002-10-28
ATE253045T1 (de) 2003-11-15
SK16242000A3 (sk) 2001-06-11

Similar Documents

Publication Publication Date Title
CN1083448C (zh) 1-苯基-4-苄基哌嗪化合物多巴胺受体亚型的特异性配体(d4)
CN1056611C (zh) 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
CN1102596C (zh) 5H－噻唑并[3,2－a]嘧啶衍生物
CN1152857C (zh) 用作多巴胺受体的苯磺酰胺-苯乙胺
CN1311773A (zh) 神经肽y5受体拮抗剂
CN1036389C (zh) 4-氨基-2，6-二甲基苯磺酰基硝基甲烷的苯乙酰衍生物或其制备方法
CN1535146A (zh) 用作5－ht6和/或5－ht75－羟色胺受体的配体的5－卤代－色胺衍生物
CN1780615A (zh) 氮杂环丁烷羧酰胺衍生物在疗法中的用途
CN100343227C (zh) 坦洛新的拆分方法
JPWO1999007667A1 (ja) 新規なエチルアミン誘導体
CN1450994A (zh) 用于治疗青光眼的6－羟基－吲唑衍生物
CN1172469A (zh) 作为选择性多巴胺d3配体的2－氨基－1,2－二氢化茚
JP2009143940A (ja) ２−フェニルベンゾチアゾリン誘導体またはその塩類からなるκオピオイド受容体アゴニスト
CN1795176A (zh) 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
CN1037269C (zh) 3-喹宁环基酯的制备方法
CN1293071C (zh) 用于治疗青光眼和近视的苯并[g]喹啉衍生物
CN1127250A (zh) 2，3-桥连的1，4-二氢吡啶类化合物及其制法和其药用
CN1167694C (zh) 1-苯基-4-(1-[2-芳基]环丙基)甲基哌嗪:多巴胺受体配体
US5472966A (en) Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
CN1268938A (zh) 氨基环烷烃化合物
CN1014992B (zh) 喹唑啉二酮和吡啶并嘧啶二酮的制备方法
HK1036049B (en) Phenylsulfonamide-phenylethylamines useful as dopamine receptors
CN1867548A (zh) 3－氮杂双环[3.1.0]己烷衍生物的制备
CN1681803A (zh) 芳酰基－哌啶衍生物
CN1135228C (zh) 用于治疗抑郁症的n-芳氧基乙基-吲哚基-烷基胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee